Table 3. Clinical characteristics.
| Variables | n | (%) |
|---|---|---|
| Gender | ||
| Male | 80 | 77.7 |
| Female | 23 | 22.3 |
| Age (year) | ||
| median | 59 | |
| range | 21–80 | |
| ECOG | ||
| 0 | 38 | 36.9 |
| 1 | 65 | 63.1 |
| Hepatitis | ||
| None | 2 | 1.9 |
| HBV | 73 | 70.9 |
| HCV | 9 | 8.7 |
| Others | 19 | 18.4 |
| Liver cirrhosis | ||
| No | 32 | 31.1 |
| Yes | 71 | 68.9 |
| AFP (IU/mL) | ||
| ≤400 | 67 | 65.0 |
| >400 | 36 | 35.0 |
| Child-Pugh score before RT | ||
| A5 | 61 | 59.2 |
| A6 | 30 | 29.1 |
| B7 | 12 | 11.7 |
| TNM stage | ||
| II | 14 | 13.6 |
| III | 81 | 78.6 |
| IVA | 8 | 7.8 |
| Previous treatment | ||
| None | 7 | 6.8 |
| TACE | 95 | 92.2 |
| RFA | 8 | 7.8 |
| PEI | 8 | 7.8 |
| Chemotherapy | 14 | 13.6 |
Abbreviations: ECOG PS = Eastern Cooperative Oncology Group performance status; HBV = hepatitis B virus; HCV = hepatitis C virus; PVTT = portal vein tumor thrombosis; AFP = alpha-fetoprotein; TACE = transcarterial chemoembolization; RFA = radiofrequency ablation; PEI = percutaneous ethanol injection